NOI to Sole Source to QuVa Pharma, Inc.
Deadline:06 May 2026, 09:00 GMT-4
Tender information
SAM.govBETHESDA, United States
- Type
- Presolicitation
- Procedure
- Presolicitation
- Ref. number
- 5816fd15c86b44d69534709710fa32ff
- NAICS
- 325412
The purpose of this acquisition is to purchase 503b compounded Intravenous (IV) Narcotics for patient care. Market research has been conducted with only two responses, from QUVA, the known Compounder and distributor for …